Krystal Biotech (KRYS) vs Kymera Therapeutics (KYMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed Krystal Biotech (KRYS) over the past year, gaining 94.2% versus a gain of 74.9%. Over five years, KRYS leads with a +571.8% price change compared with +91.1% for KYMR. Krystal Biotech is the larger company by market cap ($9.69 billion vs $8.99 billion), about 1.1 times the size.
Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus -794.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRYS | KYMR |
|---|---|---|
| Share price | $327.30 | $109.30 |
| Market cap | $9.69B | $8.99B |
| 1-day change | +0.84% | +0.88% |
| YTD return | +32.76% | +40.47% |
| 1-year return | +74.86% | +94.17% |
| 5-year return | +571.80% | +91.08% |
| P/E ratio (TTM) | 41.02 | — |
| Forward P/E | 35.33 | — |
| EPS (TTM) | $7.98 | $-3.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $389.13M | $39.21M |
| Revenue growth (YoY) | +33.94% | -16.70% |
| Net income (latest FY) | $204.83M | $-311.35M |
| Gross margin | — | 0.00% |
| Operating margin | 41.45% | -891.07% |
| Net margin | 52.64% | -794.04% |
| 52-week high | $382.54 | $130.05 |
| 52-week low | $179.19 | $55.26 |
| Distance from 52-week high | -14.44% | -15.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +19.80% | +27.47% |
| Average volume | 381.18K | 698.42K |
| Shares outstanding | 29.60M | 82.26M |
| Employees | 295 | 273 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYMR has outperformed KRYS by 19.3 percentage points over the past year.
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
- Krystal Biotech grew revenue faster in its latest fiscal year (+33.94% vs -16.70%).
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
KRYS vs KYMR FAQ
Which is bigger, Krystal Biotech or Kymera Therapeutics?
Krystal Biotech (KRYS) is larger, with a market capitalization of $9.69B compared with $8.99B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, KRYS or KYMR?
KYMR returned +94.17% over the past 12 months, compared with +74.86% for KRYS (price return, excluding dividends). Past performance does not predict future results.
Are Krystal Biotech and Kymera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.